Sunnie Kim, MD

Dr. Kim shares that she favors the zanidatamab triplet for patients with HER2-positive, PD-L1-negative disease.

Drs Kim and Pereira address diarrhea, the most notable toxicity associated with zanidatamab-based regimens in HERIZON-GEA-01.

Drs Kim and Pereira discuss one of the most unexpected findings of HERIZON-GEA-01.

Dr. Kim reviews the primary results of HERIZON-GEA-01. Both zanidatamab-containing arms significantly improved progression-free survival vs trastuzumab plus chemotherapy, with a similar magnitude of benefit.

Allan Lima Pereira, MD, of Moffitt Cancer Center, and Sunnie Kim, MD, of University of Colorado Cancer Center, open their discussion by reviewing how first-line treatment for HER2-positive gastroesophageal adenocarcinoma (GEA) has evolved.

Sunnie Kim, MD, contextualizes the use of tislelizumab as a frontline treatment option in advanced esophageal squamous cell carcinoma.